Last updated 2026-07-20
- Raised $16M Series A led by Grove Ventures, Feb 2026
- Raised $5.5M Seed round led by TLV Partners, Feb 2022
Total raised
$21.5M
Last: Undisclosed Round 2026-03
Stage
Series A
Founded
2022
Headcount
25
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Scala Biodesign is a Tel Aviv, Israel-based biotechnology company that develops computational protein design technologies to accelerate the development of protein-based medicines and biological products. Their flagship platform, ScalaOS, is a cloud-based tool that integrates physics-based modeling, evolutionary data, and AI models to design and optimize proteins more efficiently, often in a single design cycle. This approach aims to shorten development cycles, which traditionally are time-consuming, costly, and prone to failure. Scala's technology is used by pharmaceutical and biotechnology companies to develop more active and stable proteins at earlier stages of drug development. The company's platform has been adopted by nine of the world's top 20 pharmaceutical companies.
Funding history · 2 rounds · $21.5M total
2026-02
A Round
$16.0M
★ Grove VenturesIT-FarmTLV PartnersDeep InsightBullet VenturesIsrael Innovation Authority
2022-02
Seed
$5.5M
★ TLV Partners
Headcount over time
From 6 (2023-03) to 24 (2026-03) · +18 (+300%) · 16 points · source: Finder history + radar grounding
Q&A
- What is Scala Biodesign's primary focus?
- Scala Biodesign specializes in computational protein design, developing solutions for complex protein development challenges in the pharmaceutical, chemical, diagnostics, and food sectors.
- When was Scala Biodesign founded?
- Scala Biodesign was founded in March 2022.
- What is Scala Biodesign's current employee count?
- Scala Biodesign has 11-50 employees.
- Who are the key leaders at Scala Biodesign?
- Scala Biodesign is led by Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), with Prof. Sarel Fleishman serving as Chief Scientist.
- What was Scala Biodesign's initial funding round?
- In March 2022, Scala Biodesign raised $5,500,000 in a funding round led by.
- What was Scala Biodesign's most recent funding round?
- In March 2026, Scala Biodesign raised $16,000,000 in a funding round led by.
- What is the total amount of funding Scala Biodesign has raised to date?
- Scala Biodesign has raised a total of $21,500,000.
- From where did Scala Biodesign license its core technology?
- Scala Biodesign licensed its core technologies from the Weizmann Institute of Science, developed in the group of Prof. Sarel Fleishman.
- In which sectors does Scala Biodesign operate?
- Scala Biodesign operates in the Health Tech & Life Sciences, Pharma & Medical Biotechnology, and Drugs Discovery & Development sectors.
Team · 3
Dr. Ravit Netzer
Founder · Co-founder & CEO
Dr. Adi Goldenzweig
Founder · Co-founder & CTO
Prof. Sarel Fleishman
Founder · Chief Scientist
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceBiologicals
Target customers
Agriculture & FoodHealthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsagricultureproteinsbiotechnologyfoodtechchemicals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | scala-bio.com/ |
|---|---|
| linkedin.com/company/90994251 |
Identifiers & details
| Founded | 2022 |
|---|---|
| Employees (exact) | 25 |
Radar intelligence
Web history (Wayback)
| Domain | scala-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516575909 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-03-07 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 4 — people (1), shares_capital (2), annual_report (1) |
| Registered address | עין זיתים 4 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-29 | עדכון דירקטורים-הוספת דירקטור |
| 2026-03-26 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2026-01-19 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2026-05-12 | הקצאת מניות |